FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Syndicate content

Emergent BioSolutions related Press Releases

Emergent BioSolutions Provides Preliminary 2011 Financial Results and Provides Guidance for 2012

Posted January 9, 2012

ROCKVILLE, Md.--(BUSINESS WIRE)-- Emergent BioSolutions Inc. (NYSE: EBS) today announced preliminary 2011 financial results and provided guidance for 2012. For 2011, the Company anticipates total Read more...

Emergent Initiates Phase 2 Study of TRU-016 in Combination with Bendamustine in Patients with Relapsed Chronic Lymphocytic

Posted December 28, 2011

ROCKVILLE, Md.--(BUSINESS WIRE)-- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 2 study (protocol 16201) of TRU-016 in combination with bendamustine for patients Read more...

Results of Emergent BioSolutions Phase 1a Study on Adjuvanted BioThrax Anthrax Vaccine Published in the Journal Vaccine

Posted September 1, 2011

Results of Emergent BioSolutions Phase 1a Study on Adjuvanted BioThrax Anthrax Vaccine Published in the Journal Vaccine Subjects had a stronger, more rapid immune response when the adjuvant CPG 7909 Read more...

Emergent BioSolutions (EBS)' Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation

Posted June 16, 2011

ROCKVILLE, Md.--(BUSINESS WIRE)-- Emergent BioSolutions Inc. (NYSE:EBS - News) announced today that its investigational anthrax vaccine, NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), Read more...

Emergent BioSolutions Keynotes BARDA Industry Day

Posted June 6, 2011

--(BUSINESS WIRE)-- The threat of biological agents such as anthrax is real. Contracting for countermeasures, the U.S. government works with industry in its preparedness efforts to protect the Read more...

Oxford-Emergent Tuberculosis Consortium Vaccinates Last Infant in Phase IIb Clinical Trial

Posted May 5, 2011

Total of 2,784 infants vaccinated in TB efficacy trial evaluating MVA85A Study results expected to be available as early as mid-2012 ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. Read more...

U.S. Government Expands BioThrax Procurement Contract to 17.92M Doses from 14.5M Increasing Contract Value by up to $101 Million

Posted May 4, 2011

ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a modification to its current procurement contract (200-2009-30162) with the U.S. government Read more...

Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress

Posted April 14, 2011

ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) announced today that Fuad El-Hibri, its chairman and chief executive officer, has been recognized as Biotech CEO of the Year Read more...

Life Science Innovation Northwest 2011 Features Prominent Life Science Executives and Thought Leaders in Conference Line U

Posted February 3, 2011

- Unprecedented support received from regional conference underwriters - SEATTLE--(BUSINESS WIRE)-- Life Science Innovation Northwest 2011, the Pacific Northwest’s premier investor and strategic Read more...

Emergent BioSolutions (EBS) Receives Fast Track Designation for Its Investigational Monoclonal Antibody

Posted October 1, 2010

Emergent BioSolutions (EBS) Receives Fast Track Designation for Its Investigational Monoclonal Antibody for the Treatment of Inhalational Anthrax ROCKVILLE, Md.--(BUSINESS WIRE)-- Emergent Read more...
123next ›last »